Headlines and Feed
Chances of treating resistant bacterial increase with a Swedish breakthrough
Monday, 10 September 2012
There may be increased possibility of treating the hitherto most
resistant bacteria NDM, as Swedish researchers at the University of
Uppsala have hit a breakthrough.
In a test, for the first time a trail was conducted which had to do
with a combination of various antibiotics, which, some of them where
idle, but when combined, they made the infection treatable. The results
is presented at an international congress of infection in San
Francisco, USA on Monday.
Thomas Tängdén, infectious diseases researcher at the Uppsala
University Hospital told radio Sweden "we have found new combinations
of antibiotics that are effective. Although the bacteria are resistant
to individual preparations, one can get a good killing effect on
bacteria by combining them. We have lab tested on four bacterial
strains and for many of these combinations, it's all there."
What the researchers have done is in effect, make use of the older
antibiotics that have been stopped using because of factors such as
side effects. Together they have a good effect against the most
resistant bacteria NDM and the like.
Sweden, there are about 20 infected patients with resistance to
antibiotics according to statistics from the Infectious Diseases
Institute. However, it is still too early to determine whether this can
be recommended to the patients with NDM and similar bacteria, according
to Thomas Tängdén, for there are also risks.
NDM-1 is an enzyme produced by certain bacteria, which allows them to
neutralise the harmful effects of carbapenems, one of the most powerful
types of antibiotics available to doctors.
Its origin has been identified from its name. New Delhi
metallo-ß-lactamase-1 has also been identified in UK patients who had
recently travelled to India or Pakistan for medical treatment -
often-cosmetic surgery. When these people were later treated in UK or
US hospitals, NDM-1 passed to other patients.
"In general, critically ill patients are often cared for in intensive
care. They usually have other underlying diseases that make them to
remain in trouble and one do not know how to treat them. So it is a
safety all the time. There is a balance between risk and benefit."
Infectious diseases around the world are increasingly facing difficult
problems when multi-resistant bacteria spread. Being forced to use
treatments that are not sufficiently tested to patients to seeking
their survival is unfortunate, according to Professor Otto Cars,
speaking to radio Sweden.
"There is too little knowledge. Doctors are forced to experiment
without proper scientific support. Here is a great neglected area of
And before new treatments may be recommended by the regulatory
agencies, there is the need for rigorous testing on people, not only in
the test tube, and that is a dilemma," says Otto Cars.
"We will not have neither the time nor the money to wait for new
clinical trials, but we must use the knowledge that is made in the
laboratory much more," he added.
In places such as India the growing mixture and free available of
anti-biotics means the explosion resistance bacteria that would not be
treated with traditional anti biotics.
So authorities are also pointing the growing climate change, method of
food cultivation and preservation, expansion of economic development
even in the developing countries makes the natural environment weaker
in assisting in the challenge against bacteria, which have also evolved
to counter the changing environment.
Read m ore about NDM here
By Scancomark.com team
What do you think about this article? Would like to leave comments? Join our network!